Sage Therapeutics (SAGE) PT Slashed to $58 at Stifel on Caution Over zuranolone, Notes that Overall Data Package Should be Enough for Approval
Tweet Send to a Friend
Stifel analyst Paul Matteis lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $58.00 (from $75.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
